Literature DB >> 26912917

Immune Globulin Intravenous: Myasthenia Gravis (Acute Exacerbation).

Joyce A Generali1, Dennis J Cada2.   

Abstract

This Hospital Pharmacy feature is extracted from Off-Label Drug Facts, a publication available from Wolters Kluwer Health. Off-Label Drug Facts is a practitioner-oriented resource for information about specific drug uses that are unapproved by the US Food and Drug Administration. This new guide to the literature enables the health care professional or clinician to quickly identify published studies on off-label uses and determine if a specific use is rational in a patient care scenario. References direct the reader to the full literature for more comprehensive information before patient care decisions are made. Direct questions or comments regarding Off-Label Drug Uses to jgeneral@ku.edu.

Entities:  

Year:  2015        PMID: 26912917      PMCID: PMC4750826          DOI: 10.1310/hpj5009-773

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN: 0018-5787


  7 in total

1.  Comparison of IVIg and PLEX in patients with myasthenia gravis.

Authors:  D Barth; M Nabavi Nouri; E Ng; P Nwe; V Bril
Journal:  Neurology       Date:  2011-05-11       Impact factor: 9.910

2.  Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: a randomized double-blind clinical trial.

Authors:  Philippe Gajdos; Christine Tranchant; Bernard Clair; Francis Bolgert; Bruno Eymard; Tanya Stojkovic; Shahram Attarian; Sylvie Chevret
Journal:  Arch Neurol       Date:  2005-11

Review 3.  Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Authors:  H S Patwa; V Chaudhry; H Katzberg; A D Rae-Grant; Y T So
Journal:  Neurology       Date:  2012-03-27       Impact factor: 9.910

4.  Guidelines for treatment of autoimmune neuromuscular transmission disorders.

Authors:  G O Skeie; S Apostolski; A Evoli; N E Gilhus; I Illa; L Harms; D Hilton-Jones; A Melms; J Verschuuren; H W Horge
Journal:  Eur J Neurol       Date:  2010-04-12       Impact factor: 6.089

5.  IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial.

Authors:  Lorne Zinman; Eduardo Ng; Vera Bril
Journal:  Neurology       Date:  2007-03-13       Impact factor: 9.910

6.  EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases.

Authors:  I Elovaara; S Apostolski; P van Doorn; N E Gilhus; A Hietaharju; J Honkaniemi; I N van Schaik; N Scolding; P Soelberg Sørensen; B Udd
Journal:  Eur J Neurol       Date:  2008-09       Impact factor: 6.089

7.  Guidelines on the use of intravenous immune globulin for neurologic conditions.

Authors:  Tom Feasby; Brenda Banwell; Timothy Benstead; Vera Bril; Melissa Brouwers; Mark Freedman; Angelika Hahn; Heather Hume; John Freedman; David Pi; Louis Wadsworth
Journal:  Transfus Med Rev       Date:  2007-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.